GBM, One Of The Deadliest Cancers, Could Have New Hope With Novel Drug
- 2 months ago
John Climaco, CEO of CNS Pharmaceuticals was recently a guest on Benzinga's All-Access.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS).
The company’s lead drug candidate, Berubicin, is a novel drug that appears to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS).
The company’s lead drug candidate, Berubicin, is a novel drug that appears to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.